Comparison of Effects of Gliclazide, Metformin and Pioglitazone Monotherapies on Glycemic Control and Cardiovascular Risk Factors in Patients with Newly Diagnosed Uncontrolled Type 2 Diabetes Mellitus

---

Copy For Citation

EREM C., OZBAS H. M., NUHOĞLU İ., DEGER O., CIVAN N., ERSOZ H. O.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.122, no.5, pp.295-302, 2014 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 122 Issue: 5
• Publication Date: 2014
• Doi Number: 10.1055/s-0034-1370989
• Journal Name: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.295-302
• Keywords: gliclazide-MR, metformin, pioglitazone, type 2 diabetes, cardiovascular risk factors, glycemic control, NECROSIS-FACTOR-ALPHA, INSULIN-RESISTANCE, MODIFIED RELEASE, ENDOTHELIAL FUNCTION, DOUBLE-BLIND, ROSIGLITAZONE, MARKERS, PLASMA, HOMOCYSTEINE, INFLAMMATION
• Karadeniz Technical University Affiliated: Yes

Abstract

Objective: The objective of this study was to evaluate and compare the effects of gliclazidemodified release (gliclazide-MR), metformine (MET) and pioglitazone (PIO) monotherapies on glycemic control and conventional/non-conventional cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus (T2DM).